Hsp90 inhibition with resorcylic acid lactones (RALs)

Current Topics in Medicinal Chemistry

Volumn 9, Issue 15, 2009, Pages 1419-1435

  Winssinger, Nicolas ^a   Fontaine, Jean Gonzague ^a   Barluenga, Sofia ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; POCHONIN A; POCHONIN B; POCHONIN C; POCHONIN D; POCHONIN E; POCHONIN G; POCHONIN I; POCHONIN J; POCHONIN L; POCHONIN N; POCHONIN O; POCHONIN P; PROCAINE PENICILLIN ALUMINIUM MONOSTEARATE; RADICICOL; RESORCYCLIC ACID LACTONE; TANESPIMYCIN; TETRAHYDROMONORDEN; UNCLASSIFIED DRUG; ZEARALENONE; ADENOSINE TRIPHOSPHATE; HEAT SHOCK PROTEIN 90; MACROLIDE;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; BIOSYNTHESIS; BREAST CANCER; CLINICAL TRIAL; CYCLIZATION; DRUG RESEARCH; DRUG SYNTHESIS; EPOXIDATION; HALOGENATION; HUMAN; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; OXIDATION; PHARMACOPHORE; PROSTATE CANCER; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; SYNTHESIS;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MACROLIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74249106421     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789895665     Document Type: Review

References (100)

1. Delmotte, P.; Delmotte-Plaquee, J. A new antifungal substance of fungal origin. Nature 1953, 171, 344.
2. Winssinger, N.; Barluenga, S. Chemistry and biology of resorcylic acid lactones. Chem. Commun. 2007, 22-36.
3. Barluenga, S.; Dakas, P.; Boulifa, M.; Moulin, E.; Winssinger, N.; Resorcylic acid lactones: A pluripotent scaffold with therapeutic potential. C. R. Chem. 2008, 11, 1306-1317.
4. Hofmann, T.; Altmann, K.-H. Resorcylic acid lactones as new lead structures for kinase inhibition. C. R. Chim. 2008, 11, 1318-1335.
5. Turbyville, T. J.; Wijeratne, E. M.; Liu, M. X.; Burns, A. M.; Seliga, C. J.; Luevano, L. A.; David, C. L.; Faeth, S. H.; Whitesell, L.; Gunatilaka, A. A. Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. J. Nat. Prod. 2006, 69, 178-184.
6. Isaka, M.; Suyarnsestakorn, C.; Tanticharoen, M.; Kongsaeree, P.; Thebtaranonth, Y. Aigialomycins A-E, new resorcylic macrolides from the marine mangrove fungus Aigialus parvus. J. Org. Chem. 2002, 67, 1561-1566.
7. Dong, J.; Zhu, Y.; Song, H.; Li, R.; He, H.; Liu, H.; Huang, R.; Zhou, Y.; Wang, L.; Cao, Y.; Zhang, K. Nematicidal resorcylides from the aquatic fungus Caryospora callicarpa YMF1.01026. J. Chem. Ecol. 2007, 33, 1115-1126.
8. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9, 28-39.
9. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42, 260-266.
10. Boyd, M. R.; Farina, C.; Belfiore, P.; Gagliardi, S.; Kim, J. W.; Hayakawa, Y.; Beutler, J. A.; McKee, T. C.; Bowman, B. J.; Bowman, E. J. Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J. Pharmacol. Exp. Ther. 2001, 297, 114-120.
11. Moulin, E.; Zoete, V.; Barluenga, S.; Karplus, M.; Winssinger, N. Design, Synthesis, and Biological Evaluation of HSP90 Inhibitors Based on Conformational Analysis of Radicicol and Its Analogues. J. Am. Chem. Soc. 2005, 127, 6999-7004.
12. Bergerat, A.; de Massy, B.; Gadelle, D.; Varoutas, P. C.; Nicolas, A.; Forterre, P. An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature 1997, 386, 414-417.
13. Dutta, R.; Inouye, M. GHKL, an emergent ATPase/kinase superfamily .Trends Biochem. Sci. 2000, 25, 24-28.
14. Besant, P. G.; Lasker, M. V.; Bui, C. D.; Turck, C. W. Inhibition of branched-chain alpha-keto acid dehydrogenase kinase and Sln1 yeast histidine kinase by the antifungal antibiotic radicicol. Mol. Pharmacol. 2002, 62, 289-296.
15. Gadelle, D.; Bocs, C.; Graille, M.; Forterre, P. Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol. Nucleic Acids Res. 2005, 33, 2310-2317.
16. Guarnieri, M. T.; Zhang, L.; Shen, J.; Zhao, R. The Hsp90 inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ. J. Mol. Biol. 2008, 379, 82-93.
17. Ki, S. W.; Ishigami, K.; Kitahara, T.; Kasahara, K.; Yoshida, M.; Horinouchi, S. Radicicol binds and inhibits mammalian ATP citrate lyase. J. Biol. Chem. 2000, 275, 39231-39236.
18. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N.Y. Acad. Sci. 2007, 1113, 202-216.
19. Neckers, L.; Neckers, K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin. Emerg. Drugs 2005, 10, 137-149.
20. Taldone, T.; Sun, W.; Chiosis, G. Discovery and development of heat shock protein 90 inhibitors. Bioorg. Med. Chem. Lett. 2009, 17, 2225-2235.
21. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.
22. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 2008, 8, 370-374.
23. Sittler, A.; Lurz, R.; Lueder, G.; Priller, J.; Lehrach, H.; Hayer-Hartl, M. K.; Hartl, F. U.; Wanker, E. E. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 2001, 10, 1307-1315.
24. Waza, M.; Adachi, H.; Katsuno, M.; Minamiyama, M.; Sang, C.; Tanaka, F.; Inukai, A.; Doyu, M.; Sobue, G. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 2005, 11, 1088-1095.
25. Luo, W.; Dou, F.; Rodina, A.; Chip, S.; Kim, J.; Zhao, Q.; Moulick, K.; Aguirre, J.; Wu, N.; Greengard, P.; Chiosis, G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl. Acad. Sci. USA 2007, 104, 9511-9516.
26. Auluck, P. K.; Bonini, N. M. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 2002, 8, 1185-1186.
27. Luo, W.; Rodina, A.; Chiosis, G. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? BMC Neurosci. 2008, 9, (Suppl 2), S7.
28. Geller, R.; Vignuzzi, M.; Andino, R.; Frydman, J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 2007, 21, 195-205.
29. Rice, J. W.; Veal, J. M.; Fadden, R. P.; Barabasz, A. F.; Partridge, J. M.; Barta, T. E.; Dubois, L. G.; Huang, K. H.; Mabbett, S. R.; Silinski, M. A.; Steed, P. M.; Hall, S. E. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008, 58, 3765-3775.
30. Sharma, S. V.; Agatsuma, T.; Nakano, H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998, 16, 2639-2645.
31. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L. M. Antibiotic radicicol binds to the Nterminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998, 3, 100-108.
32. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs 1999, 17, 361-373.
33. Janin, Y. L. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry. J. Med. Chem. 2005, 48, 7503-7512.
34. Sharp, S. Y.; Jones, K.; Workman, P. HSP90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways. Cancer Drug Des. Disc. 2008, 305-335.
35. Chiosis, G.; Kang, Y.; Sun, W. Discovery and development of purine-scaffold Hsp90 inhibitors. Expert Opin. Drug Discov. 2008, 3, 99-114.
36. Sharp, S. Y.; Prodromou, C.; Boxall, K.; Powers, M. V.; Holmes, J. L.; Box, G.; Matthews, T. P.; Cheung, K.-M. J.; Kalusa, A.; James, K.; Hayes, A.; Hardcastle, A.; Dymock, B.; Brough, P. A.; Barril, X.; Cansfield, J. E.; Wright, L.; Surgenor, A.; Foloppe, N.; Hubbard, R. E.; Aherne, W.; Pearl, L.; Jones, K.; McDonald, E.; Raynaud, F.; Eccles, S.; Drysdale, M.; Workman, P. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 2007, 6, 1198-1211.
37. McDonald, E.; Jones, K.; Brough, P. A.; Drysdale, M. J.; Workman, P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 2006, 6, 1193-1203.
38. Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; de Haven Brandon, A.; Gowan, S.; Boxall, F.; Aherne, W.; Rowlands, M.; Hayes, A.; Martins, V.; Urban, F.; Boxall, K.; Prodromou, C.; Pearl, L.; James, K.; Matthews, T. P.; Cheung, K.-M.; Kalusa, A.; Jones, K.; McDonald, E.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Dymock, B.; Drysdale, M. J.; Finch, H.; Howes, R.; Hubbard, R. E.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Workman, P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68, 2850-2860.
39. Huang, K. H.; Veal, J. M.; Fadden, R. P.; Rice, J. W.; Eaves, J.; Strachan, J. P.; Barabasz, A. F.; Foley, B. E.; Barta, T. E.; Ma, W.; Silinski, M. A.; Hu, M.; Partridge, J. M.; Scott, A.; DuBois, L. G.; Freed, T.; Steed, P. M.; Ommen, A. J.; Smith, E. D.; Hughes, P. F.; Woodward, A. R.; Hanson, G. J.; McCall, W. S.; Markworth, C. J.; Hinkley, L.; Jenks, M.; Geng, L.; Lewis, M.; Otto, J.; Pronk, B.; Verleysen, K.; Hall, S. E. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J. Med. Chem. 2009, 52, 4288-4305.
40. Zhou, V.; Han, S.; Brinker, A.; Klock, H.; Caldwell, J.; Gu, X. J. A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal. Biochem. 2004, 331, 349-357.
41. Howes, R.; Barril, X.; Dymock, B. W.; Grant, K.; Northfield, C. J.; Robertson, A. G.; Surgenor, A.; Wayne, J.; Wright, L.; James, K.; Matthews, T.; Cheung, K. M.; McDonald, E.; Workman, P.; Drysdale, M. J. A fluorescence polarization assay for inhibitors of Hsp90. Anal. Biochem. 2006, 350, 202-213.
42. Kim, J.; Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J. Biomol. Screen. 2004, 9, 375-381.
43. Rowlands, M. G.; Newbatt, Y. M.; Prodromou, C.; Pearl, L. H.; Workman, P.; Aherne, W. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem. 2004, 327, 176-183.
44. Xu, W.; Mimnaugh, E.; Rosser, M. F.; Nicchitta, C.; Marcu, M.; Yarden, Y.; Neckers, L. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J. Biol. Chem. 2001, 276, 3702-3708.
45. Cox, R. J. Polyketides, proteins and genes in fungi: programmed nano-machines begin to reveal their secrets. Org. Biomol. Chem. 2007, 5, 2010-2026.
46. Zhou, H.; Zhan, J.; Watanabe, K.; Xie, X.; Tang, Y. A polyketide macrolactone synthase from the filamentous fungus Gibberella zeae. Proc. Natl. Acad. Sci. USA 2008, 105, 6249-6254.
47. Wang, S.; Xu, Y.; Maine, E. A.; Wijeratne, E. M. K.; Espinosa-Artiles, P.; Gunatilaka, A. A. L.; Molnar, I. Functional characterization of the biosynthesis of radicicol, an Hsp90 inhibitor resorcylic acid lactone from chaetomium chiversii. Chem. Biol. 2008, 15, 1328-1338.
48. Navarro, I.; Basset, J. F.; Hebbe, S.; Major, S. M.; Werner, T.; Howsham, C.; Brackow, J.; Barrett, A. G. Biomimetic synthesis of resorcylate natural products utilizing late stage aromatization: concise total syntheses of the marine antifungal agents 15G256iota and 15G256beta. J. Am. Chem. Soc. 2008, 130, 10293-10298.
49. Shinonaga, H.; Kawamura, Y.; Ikeda, A.; Aoki, M.; Sakai, N.; Fujimoto, N.; Kawashima, A. The search for a hair-growth stimulant: new radicicol analogues as WNT-5A expression inhibitors from Pochonia chlamydosporia var. chlamydosporia. Tetrahedron Lett. 2009, 50, 108-110.
50. Shinonaga, H.; Kawamura, Y.; Ikeda, A.; Aoki, M.; Sakai, N.; Fujimoto, N.; Kawashima, A. Pochonins K-P: New radicicol analogs from Pochonia chlamydosporia var. chlamydosporia and their WNT-5A expression inhibitory activities. Tetrahedron 2009, 65, 3446-3453.
51. Hellwig, V.; Mayer-Bartschmid, A.; Muller, H.; Greif, G.; Kleymann, G.; Zitzmann, W.; Tichy, H. V.; Stadler, M. Pochonins A-F new antiviral and antiparasitic resorcylic acid lactones from Pochonia chlamydosporia var. catenulata. J. Nat. Prod. 2003, 66, 829-837.
52. Schumacher, J. A.; Crockett, D. K.; Elenitoba-Johnson, K. S.; Lim, M. S. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics 2007, 7, 2603-2616.
53. Lampilas, M.; Lett, R. Convergent stereospecific total synthesis of monocillin I and monorden (or radicicol). Tetrahedron Lett. 1992, 33, 777-780.
54. Tichkowsky, I.; Lett, R. Improvements of the total synthesis of monocillin I and radicicol via Miyaura-Suzuki couplings. Tetrahedron Lett. 2002, 43, 4003-4007.
55. Garbaccio, R. M.; Stachel, S. J.; Baeschlin, D. K.; Danishefsky, S. J. Concise asymmetric syntheses of radicicol and monocillin I. J. Am. Chem. Soc. 2001, 123, 10903-10908.
56. Barluenga, S.; Moulin, E.; Lopez, P.; Winssinger, N. Solution- and solid-phase synthesis of radicicol (monorden) and pochonin C. Chem. Eur. J. 2005, 11, 4935-4952.
57. Barluenga, S.; Lopez, P.; Moulin, E.; Winssinger, N. Modular asymmetric synthesis of pochonin C. Angew. Chem. Int. Ed. Engl. 2004, 43, 3467-3470.
58. Moulin, E.; Barluenga, S.; Winssinger, N. Concise Synthesis of Pochonin A, an HSP90 Inhibitor. Org. Lett. 2005, 7, 5637-5639.
59. Agatsuma, T.; Ogawa, H.; Akasaka, K.; Asai, A.; Yamashita, Y.; Mizukami, T.; Akinaga, S.; Saitoh, Y. Halohydrin and Oxime Derivatives of Radicicol: Synthesis and Antitumor Activities Bioorg. Med. Chem. 2002, 10, 3445-3454.
60. Yamamoto, K.; Garbaccio, R. M.; Stachel, S. J.; Solit, D. B.; Chiosis, G.; Rosen, N.; Danishefsky, S. J. Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angew. Chem. Int. Ed. Engl. 2003, 42, 1280-1284.
61. Yang, Z.-Q.; Geng, X.; Solit, D.; Pratilas, C. A.; Rosen, N.; Danishefsky, S. J. New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. J. Am. Chem. Soc. 2004, 126, 7881-7889.
62. Soga, S.; Neckers, L. M.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga, S. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 1999, 59, 2931-2938.
63. Ikuina, Y.; Amishiro, N.; Miyata, M.; Narumi, H.; Ogawa, H.; Akiyama, T.; Shiotsu, Y.; Akinaga, S.; Murakata, C. Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol. J. Med. Chem. 2003, 46, 2534-2541.
64. Lei, X.; Danishefsky, S. J. Efficient synthesis of a novel resorcyclide as anticancer agent based on Hsp90 inhibition. Adv. Synth. Catal. 2008, 350, 1677-1681.
65. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. Engl. 2001, 40, 2004-2021.
66. Ritschel, J.; Sasse, F.; Maier, M. Synthesis of a benzolactone collection using click chemistry. Eur. J. Org. Chem. 2007, 78-87.
67. Day, J. E. H.; Blake, A. J.; Moody, C. J. An improved synthesis of resorcylic acid macrolactone inhibitors of Hsp90. Synlett 2009, 1567-1570.
68. Barluenga, S.; Fontaine, J. G.; Wang, C.; Aouadi, K.; Chen, R.; Beebe, K.; Neckers, L.; Winssinger, N. Inhibition of HSP90 with pochoximes: SAR and structure-based insights. 2009 doi : 10.1002/cbic.200900494.
69. Barluenga, S.; Wang, C.; Fontaine, J. G.; Aouadi, K.; Beebe, K.; Tsutsumi, S.; Neckers, L.; Winssinger, N. Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor. Angew. Chem. Int. Ed. Engl. 2008, 47, 4432-4435.
70. Chiosis, G.; Neckers, L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem. Biol. 2006, 1, 279-284.
71. Maroney, A. C.; Marugan, J. J.; Mezzasalma, T. M.; Barnakov, A. N.; Garrabrant, T. A.; Weaner, L. E.; Jones, W. J.; Barnakova, L. A.; Koblish, H. K.; Todd, M. J.; Masucci, J. A.; Deckman, I. C.; Galemmo, R. A. Jr.; Johnson, D. L. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry 2006, 45, 5678-5685.
72. Gooljarsingh, L. T.; Fernandes, C.; Yan, K.; Zhang, H.; Grooms, M.; Johanson, K.; Sinnamon, R. H.; Kirkpatrick, R. B.; Kerrigan, J.; Lewis, T.; Arnone, M.; King, A. J.; Lai, Z.; Copeland, R. A.; Tummino, P. J. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc. Natl. Acad. Sci. USA 2006, 103, 7625-7630.
73. Proisy, N.; Sharp, S. Y.; Boxall, K.; Connelly, S.; Roe, S. M.; Prodromou, C.; Slawin, A. M.; Pearl, L. H.; Workman, P.; Moody, C. J. Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol. Chem. Biol. 2006, 13, 1203-1215.
74. Basso, A. D.; Solit, D. B.; Munster, P. N.; Rosen, N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21, 1159-1166.
75. Wang, C.; Barluenga, S.; Koripelly, G. K.; Fontaine, J. G.; Chen, R.; Yu, J. C.; Shen, X.; Chabala, J. C.; Heck, J. V. Rubenstein, A., Winssinger, N., Synthesis of pochoxime prodrugs as potent HSP90 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 3836-3840.
76. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 2004, 11, 775-785.
77. Soldano, K. L.; Jivan, A.; Nicchitta, C. V.; Gewirth, D. T. Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation. J. Biol. Chem. 2003, 278, 48330-48338.
78. Spichty, M.; Taly, A., Hagn, F.; Kessler, H.; Barluenga, S.; Winssinger, N.; Karplus, M. The HSP90 binding mode of a radicicol-like E-oxime determined by docking, binding free energy estimations, and NMR 15N chemical shifts. Biophys. Chem. 2009, 143, 111-123.
79. Hagn, F.; Kessler, H. personal communication 2008.
80. Ugele, M.; Sasse, F.; Knapp, S.; Fedorov, O.; Zubriene, A.; Matulis, D.; Maier, M. E. Propionate analogues of zearalenone bind to Hsp90. Chembiochem 2009 [Epub ahead of print].
81. Wang, M.; Shen, G.; Blagg, B. S. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorg. Med. Chem. Lett. 2006, 16, 2459-2462.
82. Shen, G.; Wang, M.; Welch, T. R.; Blagg, B. S. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90. J. Org. Chem. 2006, 71, 7618-7631.
83. Shen, G.; Blagg, B. S. Radester, a novel inhibitor of the Hsp90 protein folding machinery, Org. Lett. 2005, 7, 2157-2160.
84. Clevenger, R. C.; Blagg, B. S. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Org. Lett. 2004, 6, 4459-4462.
85. Hadden, M. K.; Blagg, B. S. J. Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. J. Org. Chem. 2009, 74, 4697-4704.
86. Immormino, R. M.; Metzger, L. E.; Reardon, P. N.; Dollins, D. E.; Blagg, B. S. J.; Gewirth, D. T. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. J. Mol. Biol. 2009, 388, 1033-1042.
87. Barginear, M. F.; Van Poznak, C.; Rosen, N.; Modi, S.; Hudis, C. A.; Budman, D. R. The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr. Cancer Drug Targets 2008, 8, 522-532.
88. Zhao, R.; Davey, M.; Hsu, Y. C.; Kaplanek, P.; Tong, A.; Parsons, A. B.; Krogan, N.; Cagney, G.; Mai, D.; Greenblatt, J.; Boone, C.; Emili, A.; Houry, W. A. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005, 120, 715-727.
89. Gorre, M. E.; Ellwood-Yen, K.; Chiosis, G.; Rosen, N.; Sawyers, C. L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002, 100, 3041-3044.
90. Peng, C.; Brain, J.; Hu, Y.; Goodrich, A.; Kong, L.; Grayzel, D.; Pak, R.; Read, M.; Li, S. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007, 110, 678-685.
91. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
92. Xu, W.; Neckers, L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res. 2007, 13, 1625-1629.
93. Solit, D. B.; Basso, A. D.; Olshen, A. B.; Scher, H. I.; Rosen, N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003, 63, 2139-2144.
94. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 4152-4161.
95. Usmani, S. Z.; Bona, R.; Li, Z. 17 AAG for HSP90 inhibition in cancer - from bench to bedside. Curr. Mol. Med. 2009, 9, 654-664.
96. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 1999, 91, 1940-1949.
97. Gaspar, N.; Sharp, S. Y.; Pacey, S.; Jones, C.; Walton, M.; Vassal, G.; Eccles, S.; Pearson, A.; Workman, P. Acquired resistance to 17-allylamino-17- demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 2009, 69, 1966-1975.
98. Prodromou, C.; Nuttall, J. M.; Millson, S. H.; Roe, S. M.; Sim, T.-S.; Tan, D.; Workman, P.; Pearl, L. H.; Piper, P. W. Structural Basis of the Radicicol Resistance Displayed by a Fungal Hsp90. ACS Chem. Biol. 2009, 4, 289-297.
99. Solit, D. B.; Osman, I.; Polsky, D.; Panageas, K. S.; Daud, A.; Goydos, J. S.; Teitcher, J.; Wolchok, J. D.; Germino, F. J.; Krown, S. E.; Coit, D.; Rosen, N.; Chapman, P. B. Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008, 14, 8302-8307.
100. Munster, P. N.; Basso, A.; Solit, D.; Norton, L.; Rosen, N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res. 2001, 7, 2228-2236.